Revolutionizing Depression Treatment: The Rise of Spravato

This chapter delves into the FDA approval of Spravato, the first new nasal spray antidepressant since Prozac, and shares personal stories of its effectiveness. It also addresses the challenges and adaptations in administering the treatment, especially during the pandemic, alongside the growing acceptance within the medical community.